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Pulmonary thromboembolismAegyptin is a mosquito salivary gland protein and potent inhibitor of platelet aggregation. Aegyptin binds
to the von Willebrand factor-binding site on collagen and prevents its interaction with platelets. Because
collagen also induces plasma clotting by activation of factor XII, we evaluated the effects of aegyptin on
collagen-induced coagulation activation and how it interferes with thrombosis in three different in vivo
models. Our results demonstrate that aegyptin abolishes collagen-induced clot formation and thrombin
generation in platelet-free plasma. Aegyptin has no antithrombotic activity in the arteriovenous shunt
model (collagen-independent) but it prevents laser-induced collagen-mediated thrombus formation in
rats. Furthermore, aegyptin protects mice from collagen and epinephrine-induced thromboembolism.
Therefore, aegyptin has a dual antithrombotic mechanism: inhibition of platelet-collagen interaction
and collagen’s pro-coagulant activity. This is the ﬁrst description of a collagen-binding protein that also
inhibits collagen-mediated coagulant activity.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Damage to the vascular endothelium often results in collagen
exposure to the blood which plays an important role in the initial
stages of hemostatic plug formation upon vascular injury. The
interaction of circulating platelets with collagen is a multi-stage
process that involves several receptors that initiate cellular activa-
tion and platelet aggregation [1]. Collagen can directly interact
with either glycoprotein receptors on the platelet surface including
integrin a2b1 and glycoprotein VI (GPVI), or indirectly via binding
of von Willebrand factor (vWF) to the platelet surface through the
glycoprotein Ib/V/IX complex [2].
In addition to its well-established role in primary hemostasis,
i.e., platelet adhesion and aggregation, collagen was recently
shown to initiate blood coagulation through the intrinsic pathway
[3]. In vitro, collagen interacts with factor XII, enabling its activa-
tion and leading to subsequent thrombin generation. Therefore it
has been proposed that there exists a dual role for collagen in
thrombus formation [4].
Platelet inhibitors, such as aspirin and ADP receptor antago-
nists, or anticoagulants such as heparin, pentasaccharide and vita-
min K antagonists are the current mainstay of treatment and
prevention of thrombosis [5–6]. Although these drugs reportedlyimprove survival in patients with ischemic disorders, these drugs
also have limitations and side effects such as excessive bleeding.
Therefore, identifying novel drugs capable of preventing thrombus
formation without increasing the risk of hemorrhage has been the
focus of experimental and clinical investigations. In this context, it
has been proposed that targeting the intrinsic pathway of coagula-
tion would be advantageous for treating thromboembolic diseases
[7–8].
Salivary glands from blood-sucking animals are a rich source of
bioactive molecules that counteract hemostasis [9–11]. These mol-
ecules have been regarded as important tools for the study of the
hemostatic process, and have provided a valuable source of chem-
ical prototypes to develop antithrombotic compounds [12–13].
Aegyptin is a 30 kDa mosquito salivary gland protein that binds
to collagen (KD  6.0 nM) and inhibits platelet aggregation. Aegyp-
tin attenuates platelet adhesion to either soluble or ﬁbrillar colla-
gen and inhibits vWF interaction with collagen under static and
high-shear conditions [14]. Surface plasmon resonance identiﬁed
a high-afﬁnity interaction between RGQOGVMGF (where O is
hydroxyproline), a peptide corresponding to the collagen-binding
site for vWF, and aegyptin [15]. Aegyptin also recognizes the pep-
tides (GPO)(10) and GFOGER with low afﬁnity (micromolar range),
which represent the glycoprotein VI- and integrin alpha2beta1-
binding sites on collagen, respectively [15].
In the present study, we evaluated the effects of aegyptin on
blood clotting induced by collagen and tested its effect on different
models of induced thrombosis. Our results showed that aegyptin
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ting which may contribute to its effective antithrombotic activity
in vivo. Our data support a dual mechanism of action in which
aegyptin targets both the pro-aggregatory and the procoagulant
activities of collagen. This molecule might be regarded as an
important tool to dissect the hemostatic role of collagen in vivo
as well as a potential agent for the treatment of human cardiovas-
cular diseases.2. Material and methods
2.1. Reagents
Recombinant aegyptin was produced in 293-F cells, puriﬁed
and quantiﬁed as previously described [14]. Standard collagen
(equine ﬁbrillar type I Horm, type I/H) was purchased from
Chrono-Log Corp. (Haverstown, PA, USA). The chromogenic sub-
strate for thrombin (H-D-phenylalanyl-L-pipecolyl-L-arginine-p-
nitroaniline dihydrochloride, S-2238) was purchased from Dia-
pharma (Westchester, OH, USA). Gly-Pro-Arg-Pro amide (GPRP),
L-a-phosphatidylcholine (PC) and L-a-phosphatidylserine (PS)
were purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Phospholipid vesicles (PC/PS) composed of 75% PC/25% PS (w/w)
were prepared by sonication. Brieﬂy, phospholipids in chloroform
were dried with a stream of N2 and lyophilized. Lipids were resus-
pended in 50 mM Tris–HCl and 150 mM NaCl (pH 7.5) sonicated
for 10 min and adjusted to a ﬁnal concentration of 500 lM. Anase-
dan (xylazin) and Dopalen (ketamin) were purchased from Agrib-
rands (Rio de Janeiro, Brazil).
2.2. Animals
Male and female Wistar rats and Balb/c mice were housed un-
der controlled conditions of temperature (24 ± 1 C) and light
(12 h light starting at 7:00 a.m.), and all experiments were con-
ducted in accordance with standards of animal care deﬁned by
the Institutional Committee (Institute of Medical Biochemistry,
Federal University of Rio de Janeiro).
2.3. Plasma clotting assays
The effect of aegyptin on plasma clotting induced by collagen
was evaluated on an Amelung KC4A coagulometer (Labcon, Hep-
penheim, Germany) as previously described with slight modiﬁca-
tions [3]. The coagulation time was monitored in platelet-rich
plasma (PRP) or in platelet-poor plasma (PPP) supplemented with
10 lM PC/PS. Human blood samples were collected from healthy
donors in 3.8% trisodium citrate (9:1, v/v). PRP was obtained by
centrifugation at 800g for 10 min, and PPP was obtained by further
centrifugation at 2000g for 10 min.
Brieﬂy, 1 lM recombinant aegyptin and 50 lL collagen type I
were incubated for 10 min at 37 C before adding 50 lL of either
PRP or PPP supplemented with 10 lM PC/PS. After 10 min, clotting
was triggered by addition of CaCl2 (ﬁnal concentration 5 mM).
2.4. Measurement of thrombin generation in plasma
Thrombin generation was continuously measured in PPP sup-
plemented with 10 lM PC/PS, as previously described [11]. Brieﬂy,
50 lL PPP, 50 lL either TBS or aegyptin, and 50 lL collagen type I
(50 mg/mL) were incubated for 10 min at 37 C. The reaction was
initiated by the addition of CaCl2 (ﬁnal concentration 5 mM), and
10 lL aliquots were transferred every 10 s into microplate wells
containing 40 lL of TBS-EDTA buffer. To impair plasma clotting,
reactions were carried out in the presence of 10 mM GPRP.Thrombin activity was determined by the addition of 200 lM of
the chromogenic substrate S-2238. Hydrolysis of the substrate
was detected using a Versamax Microplate Reader (Molecular De-
vices, Menlo Park, CA, USA), equipped with a microplate mixer and
heating system. Reactions were recorded continuously at 405 nm,
for 20 min, at 37 C. The total volume of the reactions was 100 lL.
2.5. Thrombus formation in the arterio-venous shunt model
Antithrombotic activity in an extracorporeal shunt was investi-
gated as previously described [16]. Rats (both sexes, 200–250 g
body weight) were anesthetized with an intramuscular injection
of xylazine and ketamine (16 and 100 mg/kg, respectively).
Through a longitudinal incision in the skin over the trachea along
the midline, the left jugular vein and the right carotid artery were
cautiously freed from the surrounding tissue. The right carotid ar-
tery and the left jugular vein were cannulated, and a solution of
aegyptin was injected into the artery and allowed to circulate for
15 min before initiating the surgery for thrombosis induction.
Concurrently, an extracorporeal shunt was prepared. This shunt
consisted of two 6-cm pieces of polyethylene tubing (1.3 mm inner
diameter) with both ends cut at an angle; one end of each piece of
tubing was forced into the end of a central, 6-cm tube (1.6 mm in-
ner diameter) with a 5 cm length of silk thread drawn through it to
leave 1.0 cm outside the tubing at one end and 4.0 cm inside the
tubing. This shunt was ﬁlled with a heparin solution (50 U/mL).
One end of the shunt was inserted into the left jugular vein, and
the other end was subsequently inserted into the right carotid ar-
tery to establish blood circulation. After 20 min of blood circulation
through the shunt, the blood ﬂow was stopped at the arterial side
of the tubing with a pinch-clamp and the center of the extracorpo-
real shunt was isolated. From this segment, the silk thread coated
with the thrombus was carefully pulled out with the assistance of
the piece of thread that remained external to the shunt. The wet
thrombus weight was immediately determined by subtracting
the weight of the wet thread.
2.6. Photochemically induced carotid artery thrombosis in rats
The effect of aegyptin on arterial thrombosis was evaluated in
an established rat model [17]. Animals were anesthetized as de-
scribed above. The right common carotid artery was isolated
through a midline cervical incision, and the blood ﬂow was moni-
tored continuously using a 1PR Doppler ﬂow probe and a TS420
Flowmeter (Transonic Systems, Ithaca, NY). Rose bengal dye
(90 mg/kg body weight) was diluted to 60 mg/mL in PBS and
administered via slow injection (over 2 min) through the cava vein.
Just before injection, the common carotid artery was transillumi-
nated with a 1.5-mV, 540 nm green laser (#25-LGR-193–249,
Melles Griot Inc., Carlsbad, CA) immediately proximal to the Dopp-
ler probe from a distance of 3 cm. The mean carotid artery blood
ﬂow was monitored until stable occlusion occurred (deﬁned as a
blood ﬂow of 0 ml/min forP5 min), at which time the experiment
was terminated. Either aegyptin or PBS (control) was injected into
the cava vein 15 min before initiating the Rose bengal
administration.
2.7. Collagen/epinephrine-induced pulmonary thromboembolism
Balb/c mice were anesthetized with intramuscular xylazin
(16 mg/kg) followed by ketamine (100 mg/kg). Either aegyptin
(0.5 and 1.0 mg/kg) or vehicle was slowly injected into the inferior
vena cava 5 min prior to challenge. A mixture of 0.8 mg/kg collagen
and 60 lg/kg epinephrine was then injected into the inferior vena
cava. Animals still alive after 30 min were considered to be
survivors.
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Results were expressed as the mean ± standard error. All statis-
tical analyses were performed using GraphPad Prism 5 (GraphPad
Software). One-way analysis of variance (ANOVA) complemented
by the Dunnett post hoc test was used for comparisons between
test groups. Differences were considered statistically signiﬁcant
when P < 0.05.3. Results
3.1. Aegyptin abolishes collagen-mediated acceleration of human
plasma clotting
It was recently demonstrated that collagen accelerates plasma
clotting by activating the intrinsic pathway [3]. Remarkably, this
effect was observed regardless of whether phospholipids or plate-Fig. 1. Aegyptin abolishes collagen-mediated acceleration of human plasma
clotting. Either platelet poor plasma supplemented with 10 lM PC/PS vesicles (A)
or platelet-rich plasma (B) were pretreated with 1 lM aegyptin. Preparations were
then incubated with either collagen type I (50 lg/mL) or vehicle solvent (control).
Coagulation was initiated by the addition of CaCl2 (5 mM ﬁnal concentration).
Values are represented as the mean ± SE; n = 5–8; ⁄P < 0.05 vs control; #P < 0.05 vs
conditions with collagen.lets are present as procoagulant lipid surface [3]. To investigate the
possible effect of aegyptin on inhibiting the procoagulant effect of
collagen, plasma coagulation experiments were performed using
either platelet poor plasma (PPP) supplemented with PC/PS vesi-
cles or platelet rich plasma (PRP). As previously reported [3], col-
lagen signiﬁcantly accelerates plasma clotting in both PPP and
PRP (Fig. 1A and B, respectively). Aegyptin completely blocked col-
lagen-induced coagulation in both experimental conditions but
showed a more pronounced effect in the absence of platelets. In
fact, assays in the presence of 1 lM aegyptin showed a prolonga-
tion of plasma clotting by 1.5-fold, compared to control values
(451.7 ± 52.4 versus 307.3 ± 15.9 s). A possible explanation for this
observation is the binding of calcium ions to collagen [18], which
may direct interfere with time to achieve plasma clotting. This
hypothesis is reinforced by the observation that aegyptin has no
effect on plasma clotting in the absence of collagen (data not
shown).
3.2. Aegyptin delays collagen-induced thrombin generation in the
plasma
Initiation of the intrinsic pathway by collagen results in an in-
crease in thrombin generation in plasma [3]. Because aegyptin im-
paired collagen-induced coagulation, we evaluated its effect on
collagen-mediated thrombin generation in PPP. Fig. 2 shows that
addition of collagen to PPP accelerates thrombin formation and in-
creases the amount of enzyme formed in the assay. This effect is
completely blocked by the addition of recombinant aegyptin to
the assay, which caused a delay in thrombin generation and a sig-
niﬁcant reduction in thrombin formation (Fig. 2).
3.3. Aegyptin displays effective anti-thrombotic activity in vivo
The in vivo antithrombotic activity of aegyptin was evaluated by
employing three models of experimental thrombosis. We ﬁrst used
an arteriovenous shunt model in rats. This model is based on the
extracorporeal circulation of blood and is independent of collagen
exposure because it does not cause endothelial denudation [16].
Aegyptin was ineffective in counteracting thrombus formation in
this model (Fig. 3), which supports its proposed mechanism of
action.Fig. 2. Aegyptin inhibits thrombin generation in human plasma. Thrombin gener-
ation was measured by hydrolysis of S-2238 (0.2 mM) as described in the Materials
and Methods section. Curves show thrombin formed in plasma (results expressed
as Vmax, mOD/min) in either the absence or presence of collagen and aegyptin.
Each point represents mean ± SE of three independent determinations. ⁄P < 0.05 vs
control; #P < 0.05 vs conditions with collagen.
Fig. 3. Aegyptin shows no antithrombotic activity in an arteriovenous shunt model.
Aegyptin (50 or 100 lg/kg) or PBS (control) was injected into the carotid artery
15 min before initiating the surgery to induce thrombosis. The shunt was
assembled by connecting two cannulae with a slightly curved tube containing a
5 cm cotton thread and ﬁlled with heparin solution (50 U/mL). The extracorporeal
circulation was maintained for 20 min, and the thrombus formed on the cotton
thread was then removed from the shunt tube. Each bar represents the mean ± SE,
and the number of animals tested for each condition is reported here.
Fig. 4. Aegyptin prevents thrombus formation in collagen-dependent models. (A)
Effect of aegyptin on a Rose Bengal/laser-induced model in rats. Either aegyptin (50
or 100 lg/kg) or PBS (control) was injected into the cava vein of rats, and
thrombosis was induced by slow injection (over 2 min) of 90 mg/kg body weight of
Rose bengal dye into the cava vein at a concentration of 60 mg/mL. Before injection,
green light laser was applied to the site of injury from a distance of 3 cm and
remained on for 80 min or until stable occlusion occurred. (B) Effect of aegyptin on
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carotid thrombus formation model. This model is based on vessel
injury, and thrombus formation is dependent on collagen expo-
sure, which leads to both platelet and ﬁbrin accumulation [19].
In the presence of aegyptin, the amount of time to occlusion was
signiﬁcantly different between the control rats and rats treated
with 50 lg/kg of the inhibitor (19.37 ± 2.38 vs 54.57 ± 9.44 min)
(Fig. 4A). Interestingly, rats treated with 100 lg/kg of aegyptin
were resistant to arterial occlusion, and occlusion did not take
place before 60 min in all animals tested (Fig. 4A).
The efﬁcacy of aegyptin in inhibiting thrombus formation was
also measured in a murine model of lethal pulmonary thromboem-
bolism induced by intravenous infusion of collagen and epineph-
rine. Fig. 4B shows that all mice with the exception of one (14/
15) died within 5 min of i.v. administration of collagen and epi-
nephrine. In contrast, the two groups of aegyptin–treated mice
showed a signiﬁcant number of survivors (3 out of 15 at 0.5 mg/
kg and 11 out 15 at 1.0 mg/kg of aegyptin).a pulmonary thromboembolism model in mice. Mortality associated with an i.v.
injection of collagen (0.8 mg/kg) and epinephrine (60 lg/kg) after administration of
either PBS (control) or aegyptin. Animals that were alive 30 min after the challenge
were considered to be survivors. Each symbol represents one individual. ⁄P < 0.05 vs
control, ⁄⁄P < 0.01 vs control.4. Discussion
Aegyptin is a mosquito-derived protein that has been character-
ized as a high-afﬁnity ligand to collagen, thus serving a potent
inhibitor of platelet activation and aggregation [14]. Aegyptin
interacts with high afﬁnity with a peptide sequence based on the
vWF-binding domain in collagen. It also interacts with low afﬁnity
(micromolar range) with peptides corresponding to the glycopro-
tein VI- and integrin alpha2beta1-binding sites in collagen [15].
As a result, aegytin can block platelet adhesion at high shear rates
in vitro.
The recent observation that collagen ﬁbers accelerate plasma
clotting and enhance thrombin generation [3] led to evaluation
of whether aegyptin could block this ability, which could contrib-
ute to its antithrombotic effect in vivo. Our data clearly demon-
strate that aegyptin counteracts the collagen-induced
acceleration of plasma clotting. This effect has been observed inexperimental conditions employing either platelet-rich plasma or
platelet-poor plasma supplemented with procoagulant phospho-
lipids. It is concluded that the effect of aegyptin on plasma coagu-
lation is completely independent of its effect on platelets.
A number of studies employing in vivo thrombosis models in
mice have demonstrated a critical role for coagulation factor XII
in thrombus formation [20–21]. Remarkably, factor XII deﬁciency
confers protection against collagen-based models of induced
thrombosis. Deﬁciency of either factor XII or factor XI also abro-
gates collagen-induced acceleration of plasma clotting in vitro
[3]. Taken together it is proposed that collagen initiates the intrin-
sic pathway of coagulation in vivo, thus contributing to thrombin
generation and ﬁbrin deposition during thrombus formation. In
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in vivo thrombus formation in two distinct models: 1) photochem-
ically induced carotid artery thrombosis in rats and 2) pulmonary
thromboembolism due to i.v. administration of collagen and epi-
nephrine in mice. However, aegyptin was ineffective in preventing
thrombus formation in an arteriovenous shunt model, which is not
based on collagen exposure. We hypothesized that aegyptin inhib-
its thrombosis not only by blocking collagen-induced platelet re-
sponses but also by preventing the initiation of the intrinsic
pathway of blood coagulation induced by collagen.
Thrombosis, the most common cause of death in the developed
world, is a frequent result of atherosclerosis [22]. The rupture of
atherosclerotic plaques promotes the exposure of subendothelial
collagen ﬁbers, which play a signiﬁcant role in platelet deposition
[23]. Kuijpers and colleagues have developed a new animal model
that strongly suggests that collagen exposure in ruptured athero-
sclerotic plaques is essential for ﬁbrin deposition [24]. Therefore
agents that could simultaneously target the pro-aggregatory and
procoagulant functions of collagen could be potential treatments
for atherosclerosis-associated thrombosis.
In conclusion, we demonstrate that aegyptin is the ﬁrst collagen
binding protein that counteracts its ability to accelerate plasma
coagulation. Additionally, aegyptin is an effective antithrombotic
agent in models based on the collagen-induced hemostatic func-
tion. Taken together, our data indicate that aegyptin is a suitable
molecule for in vivo studies aiming to elucidate the hemostatic role
of collagen in both physiological and pathological conditions.
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